# Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases

> **NCT07184450** · PHASE1 · RECRUITING · sponsor: **Chongqing Precision Biotech Co., Ltd** · enrollment: 11 (estimated)

## Conditions studied

- Juvenile Dermatomyositis (JDM)
- Polyarticular Juvenile Idiopathic Arthritis
- Systemic Sclerosis (SSc)
- Primary Sjogren's Syndrome

## Interventions

- **BIOLOGICAL:** BCMA/CD70-targetd CAR-T

## Key facts

- **NCT ID:** NCT07184450
- **Lead sponsor:** Chongqing Precision Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-03-30
- **Final completion:** 2028-09-30
- **Target enrollment:** 11 (ESTIMATED)
- **Last updated:** 2025-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07184450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07184450, "Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07184450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*